BridgeBio Pharma Inc (BBIO)

NASDAQ
11.19
-0.38(-3.24%)
  • Volume:
    768,126
  • Day's Range:
    11.01 - 11.67
  • 52 wk Range:
    4.98 - 53.57

BBIO Overview

Prev. Close
11.56
Day's Range
11.01-11.67
Revenue
90.67M
Open
11.64
52 wk Range
4.98-53.57
EPS
-3.49
Volume
768,126
Market Cap
1.67B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,259,658
P/E Ratio
-3.33
Beta
0.708
1-Year Change
-76.94%
Shares Outstanding
148,246,309
Next Earnings Date
Nov 10, 2022
What is your sentiment on BridgeBio Pharma?
or
Vote to see community's results!

BridgeBio Pharma Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

BridgeBio Pharma Inc Analysis

BridgeBio Pharma Inc Company Profile

BridgeBio Pharma Inc Company Profile

Employees
391

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellStrong BuyStrong Sell
  • rebound
    2
    • Hardly
      0
  • what a drop yesterday ... omg
    0
    • JP Morgan -> 36,00$
      1
      • bounce backgood position to accumulate and accumulate
        0
        • this is the tough part. start buying or wait for a further drop?
          0
          • wipeout!
            0
            • 4$ today
              0
              • im gonna get it on TUE
                0
                • Should I buy today, any body ?😍
                  0
                  • surely buy shooting now
                    0